The retina's most various cell class: at least 33 amacrine subtypes modulate the dialogue between bipolar cells and retinal ganglion cells — and most do it without an axon, using dendrites for both input and output.
Cell Type
Inhibitory interneuron of the inner retina
Lineage & Origin
Retinal progenitors; fate fixed by transcription factors such as Neurod6
Primary Location
Inner nuclear layer, some displaced to the ganglion cell layer, of the retina
Key Markers
GlyT1 in AII cells, ChAT in starburst cells, tyrosine hydroxylase in dopaminergic cells
The name is Greek — a- non, makr- long, in- fiber — for the short-process cells: most amacrines lack an axon entirely.
Most are inhibitory, split between GABAergic and glycinergic classes; around fifteen percent release neither transmitter and are tagged by the transcription factor Neurod6.
By dendritic spread they sort into narrow-field cells near 70 micrometers, medium-field near 170, wide-field near 350.
Structure & Location
They operate in the inner plexiform layer, where bipolar axons meet ganglion dendrites; one cell's dendrites carry both input and output synapses.
Subtypes stratify at different depths and tile the retina as spaced mosaics — MEGF10 and MEGF11 organize the starburst mosaic in mice.
Development & Origin
Amacrines differentiate from retinal progenitors in the retina's second wave, after ganglion, horizontal and cone cells; transcription factors acting on progenitors decide each fate, Neurod6 selectively marking the non-GABA, non-glycine class.
Physiological Role
The AII amacrine bridges night vision, capturing input from rod bipolar cells and redistributing it to cone bipolars — scotopic signals entering the cone pathway.
Starburst amacrines, cholinergic and GABAergic at once, compute direction selectivity — the detection of directional motion.
Narrow-field amacrines carve ganglion receptive fields into subunits, letting some cells detect a small dot moving a small distance.
Combining bipolar and amacrine activity creates the retina's diverse output encodings — roughly twenty — sent to the brain.
Clinical Relevance
In a Parkinson's model, MPTP cuts dopaminergic amacrine number and delays electroretinogram oscillatory potentials — changes partly reversed by levodopa.
Those oscillatory potentials, a component involving these cells, act as non-invasive biomarkers in the same model.